The FDA has approved the first antisense oligonucleotide for chronic hepatitis B, giving a defined group of adults a chance to maintain viral control after stopping therapy. The benefit reached about one in five trial participants, while eligibility limits and serious safety warnings keep the advance tightly bounded.
Discovery
- searchSearch
- storefrontProducts
- hubMCP Server
- monitoringAnalytics
- query_statsSearch Terms
- workspace_premiumScore
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules